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Porter/Impacts of DTC Pharmaceutical Marketing
DIRECT-TO-CONSUMER (DTC) PHARMACEUTICAL MARKETING: IMPACTS
AND POLICY IMPLICATIONS
DAYNA M. PORTER
Grand Valley State University
In 1997, the Food and Drug Administration (FDA) issued relaxed guidelines for direct-toconsumer (DTC) pharmaceutical marketing and in response, pharmaceutical industry spending
on DTC promotion grew from $791 million in 1999 to $4.8 billion is 2006. For every $1 spent
on DTC pharmaceutical advertising, the pharmaceutical industry realizes $4.20 in increased
sales. Between 1998 and 1999, the top 25-marketed drugs were responsible for a $7.2 billion
increase in United States pharmaceutical spending. Healthcare costs rose 9.6% percent
annually from 2000 to 2004, with the largest portion of the increase attributable to rising
pharmaceutical costs. Patients look favorably upon DTC advertising of pharmaceuticals, while
physicians largely do not. DTC pharmaceutical marketing influences physician-prescribing
practices, and 60-65% of studied physicians want the practice to be scaled back or cease
entirely. DTC pharmaceutical marketing seeks to maximize profits and some patients cannot
afford advertised drugs. While the FDA does not recognize negative public health implications
due to DTC pharmaceutical marketing, current regulations have failed to quell opposition to the
practice. At a minimum, the FDA should not allow product claims advertisements, which
persuade rather than inform patients.
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DIRECT-TO-CONSUMER (DTC) PHARMACEUTICAL MARKETING: IMPACTS
AND POLICY IMPLICATIONS
The Kefauver-Harris Drug Amendment of 1962 gave legislative authority to the Food and
Drug Administration (FDA) to regulate prescription drug advertisements (Ta & Frosch, 2008).
FDA policy required advertisements to include side effects, contraindications and effectiveness
of the advertised prescription drug, and to present “fair and balanced” information (Hoek, 2008;
Ta & Frosch, 2008). Although these lengthy requirements limited the types of media
pharmaceutical companies were able to utilize, mass-media direct-to-consumer (DTC)
advertising spending rose steadily (Lyles, 2002). In 1997, the FDA issued draft guidance (later
finalized in 1999) titled Guidance for Industry on Consumer-Directed Broadcast Advertisements,
which relaxed previous requirements and allowed pharmaceutical companies to make adequate
provisions for consumers to obtain additional information on the drug through mechanisms such
as a toll-free telephone number, print materials, a webpage, or healthcare providers (Hoek, 2008;
Ta & Frosch, 2008). The pharmaceutical industry responded to this guidance by increasing DTC
expenditures exponentially, particularly in television advertising (Ta & Frosch, 2008).
In the years following release of the new FDA guidelines, pharmaceutical industry spending on
DTC grew from $791 million in 1999 to $4.5 billion in 2004 (Friedman & Gould, 2007) and $4.8
billion in 2006 (Timko & Chowansky, 2008). With increased expenditures on advertising, sales
increase. For every $1 spent on DTC pharmaceutical advertising, pharmaceutical sales within
the industry rise by roughly $4.20 (Ta & Frosch, 2008; Timko & Chowansky, 2008). The
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cholesterol-lowering statin medication, Lipitor, is an excellent example. With heavy marketing
of statins, Lipitor passed $1 billion in worldwide sales within the first year of its launch in the
United States (Lorence & Churchill, 2007). Such rapid growth in spending, lucrative industry
returns, and increased prevalence of pharmaceutical advertisements directed to consumers has
led to scrutiny of the practice by various stakeholders, including physicians and policy-makers.
Of particular interest is the impact the practice of DTC marketing of pharmaceuticals has on the
doctor-patient relationship, overall cost and demand for prescription drugs, and more
specifically, how such advertisements influence behaviors of the elderly, low income and other
vulnerable populations.
This literature review examines multiple aspects of DTC marketing of pharmaceuticals, with
an overview of the pros and cons of DTC marketing, costs and expenditures, beliefs and
behaviors of physicians and patients (consumers), the impact on vulnerable populations, and
policy implications of research findings. This in-depth analysis of existing research addresses
the question: What are the impacts of direct-to-consumer marketing of pharmaceuticals in the
United States, and is policy revision necessary?
METHODS
Literature selected for this review was obtained through Grand Valley State University Library
resources, and includes research conducted about or within the United States and written in the
English language. Selected literature is published after the 1999 finalization of the FDAs
Guidance for Industry on Consumer-Directed Broadcast Advertisements, as this guidance
dramatically changed the pharmaceutical marketing environment in the United States. Literature
included in this review provides both qualitative and quantitative data that attempts to validate
whether or not DTC marketing of pharmaceuticals is effective in increasing consumer awareness
and knowledge of conditions and treatment options, increases patient compliance with prescribed
therapies, increases drug costs, leads to unsafe consumer practices, disproportionately impacts
vulnerable populations, or detracts from the physician-patient relationship. This analysis
examines these issues from the perspectives of both the healthcare industry and patients, and
focuses on DTC pharmaceutical marketing’s impact on healthcare costs, demand, physician and
patient perceptions, policy implications of the findings, and provides a revised policy
recommendation.
Perez v Wyeth Laboratories, Inc.
One of the key protections pharmaceutical companies rely on, even when advertising
pharmaceuticals directly to consumers, is that physicians are in the best position to discuss
medication risk information with their patients. This is “a common-law doctrine called the
learned intermediary rule (LIR)” (Mello, Rosenthal, and Neuman, 2003) existing since the late
1960s when pharmaceuticals were marketed to physicians, not directly to patients (Fushman,
2000). As long as pharmaceutical companies inform physicians of medication risks via FDArequired package inserts, the LIR “…allows pharmaceutical manufacturers to discharge their
duty to warn patients of prescription drug dangers…” (Pateiro, 1999). In a landmark “…5-2
decision issued in August 1999…” (Gemperli, 2000), the New Jersey Supreme Court ruled that
the LIR “…does not apply when [pharmaceutical] companies engage in direct-to-consumer
(DTC) advertising” (Gemperli, 2000).
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Beginning in 1995, five women individually sued Wyeth-Ayerst Laboratories (Wyeth) for
failure to adequately warn of the potential side effects and surgical complications associated with
Norplant, a contraceptive implant Wyeth mass marketed to consumers in the early 1990s
(Gemperli, 2000; Pateiro, 1999). After consolidating twenty-six cases into one action, the five
women in Perez became representatives of fifty Norplant users with similar claims (Fushman,
2000; Gemperli, 2000; Pateiro, 1999). The women complained of various personal injuries, but
all alleged “…Wyeth failed to warn them of the pain and scarring that resulted from the removal
of the Norplant capsules” (Fushman, 2000). Wyeth invoked LIR in its defense, providing
evidence that their duty to warn patients was satisfied because they provided adequate risk
information to physicians (Mello et al., 2003). The New Jersey Supreme Court evaluated the
three most common LIR justifications, including: (1) manufacturers would unnecessarily intrude
upon the patient-physician relationship if they were required to provide complete risk
information directly to consumers, (2) physicians are better than manufacturers at conveying
drug risks and benefits to their patients, and (3) drug manufacturers lack the means to effectively
communicate directly with patients (Mello et al., 2000).
The court held that DTC marketing has altered physician prescribing practices due to pressure
from patients, physicians lack sufficient time in the current managed care climate to adequately
present comprehensive risks and benefits of medications to patients, and that the success of DTC
marketing campaigns clearly shows that pharmaceutical manufactures do have effective means
to communicate directly with patients (Mello et al., 2000). The court held that for companies
that advertise pharmaceuticals directly to consumers, the LIR does not apply (Mello et al., 2000)
and the case was remanded (Fushman, 2000). Although non-precedent setting outside of New
Jersey, the Perez ruling may have larger implications for shared “failure to warn” liability
between physicians, who traditionally hold all the risk, and pharmaceutical companies who
market directly to consumers (Fushman, 2000). Although arguably too broad a rule, the Perez
decision holds pharmaceutical companies accountable for advertising misinformation and does
not allow them to escape liability behind the shield of the LIR (Fushman, 2000). Faced with the
potential for new consumer lawsuits, pharmaceutical companies could face substantial costs.
However, successful pharmaceutical marketing results in wide profit margins, suggesting that
companies may absorb some of the cost or raise drug prices (Mello et al., 2000; Pateiro, 1999).
“Perez has…been cited approvingly by the Connecticut Supreme Court as an example of how
the law can adapt to changes in the health care marketplace” (Mello et al., 2000). Although the
following literature review exposes inconsistencies in research findings and highlights the need
for empirical studies, the FDA should also consider the implications of the Perez decision in
future policy development and regulation of DTC pharmaceutical marketing.
LITERATURE REVIEW
Origins
As early as 1708, Americans have been exposed to medication advertisements, with patent
medicine advertisements appearing in Boston newspapers (Friedman & Gould, 2006; Joseph et
al., 2007). Modern regulation of such advertising did not begin until 1981 when at the request of
the pharmaceutical industry; the FDA began working to clarify guidance on how DTC consumer
advertising of pharmaceuticals could align with laws in existence at that time (Joseph et al.,
2007). In 1983, the FDA began a voluntary moratorium on DTC pharmaceutical advertising
until decision-makers determined in 1985 that existing regulations were sufficient to protect
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consumers and published this notice in the Federal Register (Joseph et al., 2007). Until the late
1990s to early 2000s, however, television remained relatively unutilized as a DTC advertising
medium (Joseph et al., 2007). In 1997, the FDA issued draft guidance (later finalized in 1999)
titled Guidance for Industry on Consumer-Directed Broadcast Advertisements, which relaxed
previous requirements and allowed pharmaceutical companies to make adequate provisions for
consumers to obtain additional information on the drug through mechanisms such as a toll-free
telephone number, print materials, a webpage, or healthcare providers (Hoek, 2008; Ta &
Frosch, 2008). The pharmaceutical industry enthusiastically embraced these guidelines and DTC
pharmaceutical advertising budgets were expanded, particularly for television advertisements
(Cole, 2007; Friedman & Gould, 2006; Hoek, 2008; Joseph et al., 2005; Joseph et al., 2007;
Joseph et al., 2008; Lyles, 2002; Ta & Frosch, 2008; Timko & Chowansky, 2008; Wakeam,
2009).
Viagra is an early example of how these relaxed regulations affected the pharmaceutical
industry. Deregulation of the pharmaceutical industry and publication of the new FDA
guidelines occurred just six months before Pfizer’s release of Viagra. According to Cole (2007),
“Second only to Prozac in the race to become America’s first blockbuster drug ($1 billion in
annual sales), in 1998, Viagra news ranked just behind the coverage of the Clinton-Lewinsky
scandal.” Furthermore, in a previously unseen approach to DTC advertising, in 2002, Pfizer
promoted Viagra by making it the official sponsor of Major League Baseball and securing
former Texas Rangers first baseman, Rafael Palmeiro, as its spokesperson (Cole, 2007). Viagra
sales reached $1.74 billion in 2002 alone (Cole, 2007).
Similarly, Lipitor received market share increases because of a DTC marketing campaign
(Lorence & Churchill, 2007). Although unintentional, Bristol-Myers Squibb facilitated some of
this growth through extensive DTC marketing of Pravachol, their statin medication (Lorence &
Churchill, 2007). As noted by Lorence and Churchill (2007), however, Bristol-Myers Squibb
failed to extend this marketing to physicians, so when patients asked for cholesterol-lowering
medications, doctors prescribed Lipitor. Lipitor sales worldwide exceeded $1 billion in its first
year of release, and at $10.9 billion in 2004 sales, Lipitor was the largest selling drug in the
world (Lorence & Churchill, 2007).
Anxious to explore new marketing avenues, Johnson & Johnson, Proctor & Gamble, and
GlaxoSmithKline have secured the services of the Entertainment Resources and Marketing
Association (ERMA) (Ta & Frosch, 2008). ERMA is “an association of entertainment
marketing agencies, studio executives, and corporations who engage in the business of branded
entertainment, product placement and integration,” (Ta & Frosch, 2008). Additionally, Ta and
Frosch (2008) report that Court TV had an information booth at the 2005 Pharmaceutical
Marketing Congress. Reports of lucrative profits, non-traditional DTC marketing practices, and
potential expansion into product placements have raised red flags for many stakeholders, and
DTC pharmaceutical advertising practices have realized growing scrutiny.
In fact, the American Medical Association (AMA) and American College of Physicians (ACP)
have both released opinions regarding DTC pharmaceutical marketing (Joseph et al., 2007). The
ACP opposes DTC pharmaceutical marketing due to it undermining the patient-physician
relationship and challenging physicians’ medical judgment (Joseph et al., 2007). The AMA
finds DTC pharmaceutical marketing an acceptable practice, provided it adheres to guidelines
the AMA developed with the FDA (Joseph et al., 2007). In addition to professional
organizations, the United States Congress has recognized the potential public policy implications
of DTC marketing of pharmaceuticals. Although no legislation is enacted to date, in 2001, the
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Senate Subcommittee on Consumer Affairs, Foreign Commerce and Tourism held a hearing on
DTC pharmaceutical marketing, and in the 2004 Presidential race, candidate Howard Dean
proposed eliminating the practice and reducing Medicare reimbursement for marketers of heavily
advertised drugs (Friedman & Gould, 2006).
Oversight
Industry. In response to the growing scrutiny, the Pharmaceutical Research and Manufacturers
of America (PhRMA) developed a set of Guiding Principles in 2005 (Joseph et al., 2007) to
promote higher standards in DTC promotions (Hoek, 2008). “Among other points, the 15
principles require advertisers to ensure their communications are not misleading, that they
educate consumers and provide balanced information (including details of alternative
treatments)” (Hoek, 2008), as well as a waiting period for newly approved drugs (Joseph et al.,
2007). Additionally, the industry established the Office of Accountability, which receives
comments and issues reports about compliance with the Guiding Principles (Hoek, 2008). This
self-regulation is an attempt to quell growing concerns over DTC pharmaceutical marketing
practices, particularly in the absence of adequate FDA oversight (Hoek, 2008).
FDA. The FDA has identified three categories of DTC pharmaceutical marketing: productclaims, help-seeking advertisements, and reminder advertisements (Lyles, 2002). Product claims
“promote a specific product and must present a brief summary with a fair balance of benefits and
of risks” (Lyles, 2002). Help seeking advertisements “provide information on diseases or
conditions – they encourage consumers to consult their physicians regarding treatment options;
specific prescription drugs or treatments cannot be mentioned, nor can the advertisement contain
linkages to materials indentified with a specific product” (Lyles, 2002).
Reminder
advertisements “…cannot contain or suggest the clinical role of the product” (Lyles, 2002).
Prior to airing, the FDA reviews some advertisements and monitors promotions throughout
(Hoek, 2008). When appropriate, the FDA takes enforcement action (Hoek, 2008). Enforcement
actions include untitled or warning letters; with untitled letters outlining the alleged violations of
the Federal Food, Drug and Cosmetic Act, and warning letters carrying greater authority (Hoek,
2008). Untitled letters request a response from the responsible party and suggest corrective
actions, whereas warning letters may request “corrective advertising to dispel incorrect beliefs”
(Hoek, 2008). In a review of warning letters issued between 1997 and 2002, the most common
violations were inadequate risk information and inaccuracy of efficacy information (Hoek,
2008). “This suggests advertisers are not consistently providing a ‘fair balance’ between risk
and benefit information and raises questions about FDA oversight that the General Accounting
Office has also noted” (Hoek, 2008). Short of a total ban on DTC marketing of pharmaceuticals,
Wakeam (2009) calls for a specific government regulatory body to provide more control over
accuracy of product promotions and notes that “governmental action might be able to provide a
limit on pharmaceutical advertising as a consumer safeguard.”
In a recent example, in late 2008, Bayer HealthCare Pharmaceutical, Inc. (Bayer) President &
Chief Executive Officer, Rienhard Franzen, received an official FDA Warning Letter from
Thomas Abrams, Director of the FDA Division of Drug Marketing, Advertising, and
Communications (DDMAC) for YAZ, an oral contraceptive that Bayer was marketing as also
effective in reducing symptoms of premenstrual syndrome (PMS) and acne, despite YAZ being
approved as an oral contraceptive effective in treating only premenstrual dysphoric disorder
(PMDD) (Abrams, 2008). In the warning letter, the FDA asserts that “…two 60-second directto-consumer (DTC) broadcast television advertisements (TV Ads)…for YAZ®…are misleading
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because they broaden the drug’s indication, overstate the efficacy of YAZ, and minimize serious
risks associated with the use of the drug…These violations are concerning from a public health
perspective because they encourage use of YAZ in circumstances other than those in which the
drug has been approved, over-promise the benefits and minimize the risks associated with YAZ”
(Abrams, 2008). The warning letter further requests that Bayer immediately discontinue
advertising YAZ without revising the promotional materials to reflect the FDAs suggested
corrective language, and offers DDMAC assistance with developing new materials. Mr. Abrams
(2008) closes with a warning that “Failure to correct the violations…may result in FDA
regulatory action, including seizure or injunction, without further notice.”
Implications
Pros and Cons. Researchers agree on common pros of DTC pharmaceutical marketing.
Advocates of DTC pharmaceutical marketing argue that it increases consumer awareness of
common conditions and available treatment options; results in greater patient empowerment and
assertiveness in health care; improves physician-patient communication; and enhances patient
compliance with prescribed therapies (Hoek, 2008; Joseph, Spake & Finny, 2008; Joseph, Spake
& Godwin, 2007; Joseph et al., 2005; Lyles, 2002; Ta & Frosch, 2008; Timko & Chowansky,
2008).
Opponents consistently assert that DTC advertising campaigns for pharmaceuticals lack
information about alternate therapies, efficacy, and cost, and often provide inappropriate or
misleading information for target audiences (Beltramini, 2006; Hoek, 2008; Joseph et al., 2007;
Joseph et al., 2008; Lyles, 2002; Ta & Frosch, 2008; Timko & Chowansky, 2008). Additionally,
opponents believe the physician-patient relationship is hindered, patients opt for advertised
remedies as “quick-fix” options even when the therapy may not be appropriate and may be
unsafe, and the costs of pharmaceuticals and medical care in general are increased due to DTC
marketing of pharmaceuticals (Beltramini, 2006; Hoek, 2008; Joseph et al., 2007; Joseph et al.,
2008; Lyles, 2002; Ta & Frosch, 2008; Timko & Chowansky, 2008). Many of the cons
expressed in the research are consistent with the holdings of the New Jersey Supreme Court in
Perez v. Wyeth Laboratories, Inc.
Costs. Researchers agree that subsequent to the relaxation of federal guidelines on DTC
pharmaceutical advertising in 1997 (finalized in 1999), pharmaceutical industry spending on
such advertising campaigns has grown exponentially (Cole, 2007; Friedman & Gould, 2006;
Hoek, 2008; Joseph et al., 2005; Joseph et al., 2007; Joseph et al., 2008; Lyles, 2002; Ta &
Frosch, 2008; Timko & Chowansky, 2008; Wakeam, 2009). Cole (2007) asserts that one year
after the FDA loosened restrictions on DTC pharmaceutical advertising, pharmaceutical
companies increased their advertising budgets by 400% and redirected marketing from
physicians to their patients. Table 1 lists pharmaceutical industry spending on DTC advertising
in various years ranging from 1991 to 2006 as reported in the literature, which captures the
relaxation of federal regulations in 1997. In some instances, reported expenditures vary by
researcher.
Researchers agree that for every $1 spent on DTC advertising campaigns, sales within the
pharmaceutical industry increase by $4.20 (Ta & Frosch, 2008; Timko & Chowansky, 2008).
From 1996 to 2000, pharmaceutical industry spending grew 216% in absolute dollars, with the
majority of the increase concentrated in roughly 24 brands, representing a 34% increase in all
prescription drug spending from 1998-1999 alone (Lyles, 2002). Between 1998 and 1999, the
top 25-marketed drugs were responsible for an increase in United States pharmaceutical costs by
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$7.2 billion (Joseph et al., 2005). From 1999-2000, the costs of 50 of the most heavily
advertised drugs rose 32%, compared to a 14% increase for all other drugs combined (Joseph et
al., 2005). Joseph et al. (2007) report that healthcare costs rose in the United States 9.6%
annually from 2000 to 2004, with the largest portion of the increase attributable to rising
pharmaceutical costs.
Table 1. Pharmaceutical Industry DTC Marketing Expenditures by Year
Year
Expenditures
References
1991
$55.3 million
Joseph et al., 2008
1995
$340 million
Joseph et al., 2008
1996
$791 million
Friedman & Gould, 2006
1997
$220 million
Joseph et al., 2007
1998
$1.2 billion
Joseph et al., 2005
1999
$1.8 billion
Joseph et al., 2008
2000
$2.5 billion
Joseph et al., 2005, Timko &
Chowansky, 2008; Wakeam,
2009
2001
$2.7
Timko & Chowansky, 2008
$2.8 billion
Joseph et al., 2008
2002
$2.2 billion (first 10 months)
Joseph et al., 2005
2003
$3.2 billion
Friedman & Gould, 2006;
Joseph et al., 2007; Timko &
Chowansky, 2008
2004
$4.5 billion
Friedman & Gould, 2006
2005
$>4 billion
Hoek, 2008
$8.4 billion
Joseph et al., 2007
2006
$4.8 billion
Timko & Chowansky, 2008
However, Ta and Frosch (2008) report that annual pharmaceutical industry promotional
spending remains steady at about 14% of total spending. Pharmaceutical company advocates
assert that cost increases are attributable to massive expenditures on research and development
leading to high-demand drugs that replace traditional surgical procedures (Joseph et al., 2005).
Friedman and Gould (2006) found that from discovery to launch of a new pharmaceutical, it
takes approximately seven years and costs $800 million.
Researchers agree that the pharmaceutical industry is a leader in advertising expenditures
amongst spending categories. Some argue pharmaceutical advertising trails only the automotive
industry and fast foods, while others argue pharmaceutical advertising ranks fifth (Joseph et al.,
2007). In the first half of 2005, only the automotive industry exceeded the pharmaceutical
industry in advertising expenditures (Ta & Frosch, 2008).
Key Stakeholders
Patients. Lyles (2002) cautions that over 50% of respondents in a national poll believe their
health plan is more worried about saving money than providing the best treatment, and 25%
trust their physician less than in recent years. Beltramini (2006) reports that as a form of
information about pharmaceuticals, advertising is trusted the least. Despite this skepticism,
researchers agree that patients look favorably upon DTC advertising of pharmaceuticals, and
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acknowledge that such advertising prompts patients to seek additional information on a condition
or marketed drug (Beltramini, 2006; Hoek, 2008; Joseph et al., 2005; Joseph et al., 2007; Joseph
et al., 2008; Lyles, 2002; Ta & Frosch, 2008; Timko & Chowansky, 2008). Joseph et al. (2008)
surveyed customers at a grocery store pharmacy and found that 69% believe doctors prescribe
the most effective medications, but 52% also believe incentives from the pharmaceutical industry
play a role in prescribing behaviors. Lyles (2002) argues that DTC advertising “reflects the
consumer’s growing role in prescription drug decisions in managed care, desire for information,
and distrust in their providers.” Subsequently, many researchers have examined and documented
actual patient behaviors after exposure to DTC pharmaceutical advertisements.
Existing research indicates that DTC pharmaceutical marketing leads to changes in patient
behaviors (Joseph et al., 2008). Joseph et al. (2007) found that after viewing DTC
pharmaceutical advertisements, some patients go to their doctor based on advertised symptoms
to ask for a specific drug. If the physician does not prescribe the requested medication, some
patients go to another doctor to obtain the desired medication (Joseph et al., 2008). In 2005,
Joseph et al. found that 23-29% of patients who ask a doctor about a specific drug or condition
for the first time are doing so because of exposure to DTC pharmaceutical advertisements, and 69% request a specific drug before any dialogue occurs. Additionally, Joseph et al. (2008) found
that respondents are persuaded by DTC pharmaceutical advertisements to take action, with 41%
asking a physician for a specific drug (51% of whom receive the requested drug), and 40% going
to a doctor based on advertised symptoms. Interestingly, patients that ask physicians for
medication are more likely to receive a prescription than those who do not ask (Beltramini, 2006;
Hoek, 2008; Joseph et al., 2005; Joseph et al., 2007; Joseph et al., 2008; Lyles, 2002; Ta &
Frosch, 2008; Timko & Chowansky, 2008; Wakeam, 2009), and 29% report favoring brand
name to generic drugs (Joseph et al., 2008).
Beltramini (2006) compiled data from other existing patient-level surveys, including the 2001
Kaiser Family Foundation Understanding the Effects of Direct-to-Consumer Prescription Drug
Advertising, and 2002 Frank et al. study of “Trends in Direct-to-Consumer Advertising of
Prescription Drugs.” Frank et al. found that 91% of respondents were aware of DTC
pharmaceutical marketing, 30% talked to their doctor about an advertised medication, and 13%
received their requested prescription (Beltramini, 2006). While the Kaiser Family Foundation
found similar rates of respondents talking to their doctors about advertised medications (30%),
44% of respondents reported receiving the requested prescription as opposed to only 13% in the
Frank et al. study (Beltramini, 2006). Regardless of the source of the findings, the results all
support the notion that marketing pharmaceuticals directly to patients results in changes in
patient behavior, and suggests patients are in favor of continued DTC pharmaceutical marketing.
Vulnerable populations. Much of the existing literature examines impact of DTC
pharmaceutical marketing on patients in a broad sense. Not all patients, however, are affected in
equal measure. Several factors, including an ever-diversifying, aging population; the
implementation of Medicare Part D; and an ailing economy, have prompted researchers to focus
greater attention on traditionally more vulnerable populations including minorities, women,
senior citizens, and lower-income earners. Lyles (2002) reports variation in awareness of DTC
pharmaceutical marketing amongst different races or ethnicities, socioeconomic status and
gender; the lowest amongst minorities (particularly Hispanics) and those with annual household
incomes less than $25,000. Joseph et al. (2008) found income to be the only statistically
significant factor in patient behavior. Income earners of $80,000 or more approach their
physicians about advertised drugs less than at other income levels, and those who earn $20,000
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or less report pharmaceutical advertisements persuade them to prefer brand name drugs and to
consult a physician when they have symptoms mentioned in those advertisements (Joseph et al.,
2008). Low-income individuals and senior citizens may be less accepting of generic
medications, which is significant since costs of brand name pharmaceuticals are often much
higher than equivalent generic medications (Joseph et al., 2008).
In addition to income level differences, senior citizens have been found to be more skeptical of
DTC pharmaceutical advertisements and although most (77%) senior respondents in a 2007
study by Joseph et al. reportedly are aware of such advertising, less than half (43%) say they are
motivated to see their doctor after exposure to such ads. Additionally, despite having the highest
pharmaceutical consumption rates, senior citizens have the lowest comprehension and recall of
DTC pharmaceutical advertisements (Joseph et al., 2007).
This suggests that DTC
pharmaceutical advertisements may be ineffective at reaching some target populations.
Beltramini (2006) notes that seniors may be particularly vulnerable to DTC pharmaceutical
marketing; however, because they are “consumers who want to believe these products will solve
their problems.” In other words, many advertisements for pharmaceuticals do not influence
senior citizens until a condition or medication “hits home,” at which time, older Americans may
be disproportionately influenced to act.
Women are more likely than men to be aware of DTC marketing (Lyles, 2002, Joseph et al.,
2005) and women are more likely to approach a doctor about advertised drugs (Joseph et al.,
2007). The plaintiffs in Perez v. Wyeth Laboratories, Inc. alleged in their complaint that the
massive Norplant advertising campaign directly targeted women, not physicians (Fushman,
2000). Joseph et al. found no differences between males and females, however (2008). Since
data on gender differences are limited, future research in this area is needed, as available
information suggests gender may impact awareness and behaviors subsequent to exposure to
DTC pharmaceutical advertisements.
In addition to gender exploration, additional research into literacy levels is warranted, as Hoek
(2008) suggests that early evidence shows patients with lower literacy levels have unbalanced
comprehension and recall of DTC pharmaceutical advertisements. To understand fully the
impacts of DTC pharmaceutical marketing on patients, greater focus should be placed on more
defined patient populations to ensure disparate impacts are identified and understood, and
appropriate safeguards can be put in place to protect the most vulnerable.
Physicians
Pharmaceutical companies have long marketed directly to physicians, and Timko and
Chowansky (2008) report that physicians tend to inappropriately prescribe medications if they
rely only on information from pharmaceutical companies. Since the relaxation of FDA
regulations in 1997, pharmaceutical industry promotion budgets have grown and shifted some of
the emphasis from physician marketing to DTC marketing (Lyles, 2002), which encourages
physicians to research medications beyond the information provided by pharmaceutical
companies. While patients are generally in favor of DTC marketing of pharmaceuticals, the
literature indicates the majority of physicians are less accepting (Friedman & Gould, 2006;
Lyles, 2002; Joseph et al., 2008; Timko & Chowansky, 2008). Friedman and Gould (2006)
found 53% of surveyed physicians feel that DTC marketing of pharmaceuticals leads to patients
asking for and receiving unnecessary prescriptions, and 66% of surveyed physicians feel this
includes an incorrect preference for brand name drugs when a generic is sufficient. Of
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responding United States physicians, 60-65% want DTC marketing of prescription drugs to
decrease or stop entirely (Joseph et al., 2008).
Despite this negative overall opinion of DTC pharmaceutical marketing, most physicians
prescribe medications to patients who expect or ask for them, including prescriptions for
specifically requested, advertised drugs, even if the physician feels it may not be the most
effective therapy (Friedman & Gould, 2006; Lyles, 2002; Timko & Chowansky, 2008). Timko
and Chowansky (2008) report that between 1994 and 2001, adolescents’ physician visits in
which psychotropic medications were prescribed rose by 250%, with the greatest increase after
1999, the first year DTC pharmaceutical advertising guidelines were relaxed. From 2000 to
2001, only 20.9% of adolescents who were prescribed psychotropic medications received an
accompanying mental health diagnosis (Timko & Chowansky, 2008).
Wakeam (2009) opines that, when faced with a choice of two comparable medications,
physicians will likely defer to patient preference, and in four out of five instances, patients are
prescribed the drugs they ask for. Over 80% of polled physicians report receiving a direct,
specific medication request, and 23.5% report altering prescribing methods because of such
requests (Timko & Chowansky, 2008). Among those physicians, only half feel the prescribed
medication was the best choice of treatment, and 5% prescribed the medicine simply to appease
the patients (Timko & Chowansky, 2008). Non-drug therapies are discussed with 53% of
patients who ask about an advertised drug, and this increases to 77% for diabetes, to 84% for
overweight patients, and for hypercholesterolemia, to 92% (Lyles, 2002).
Physicians act as gatekeepers in the health of their patients, and patients cannot obtain
prescription medications without approval of their physician. In the four quarters ending the first
quarter of 2005, United States physicians wrote 3.5 billion prescriptions (Friedman and Gould,
2006). If physicians refuse to prescribe requested medications that are inappropriate or
unnecessary, prescribe generic medications regardless of patient preference, and encourage
lifestyle modification as opposed to prescription interventions, this change in prescribing
behavior could have an impact on pharmaceutical company promotion methods. Current
physician prescribing habits do not reflect the reported desires of 60-65% of United States
physicians for DTC pharmaceutical marketing to be scaled back or eliminated entirely (Joseph
et al., 2008).
POLICY DISCUSSION
DTC marketing of pharmaceuticals is often used to promote new drugs, prior to loss of patent
protection, in a way that maximizes profits (Hoek, 2008). When patents expire, companies often
release new versions of the drug that offer improvements or differ in some other way (Hoek,
2008). While some drugs change substantially, others must rely more directly on marketing to
generate sales, shifting demand from existing, to new and more expensive drugs (Hoek, 2008).
Because many DTC promoted pharmaceuticals do not attract government subsidies, patients
must pay for the drugs, and in some instances, they are unable to afford advertised medications
(Hoek, 2008). Additionally, senior citizens and low-income individuals prefer brand name to
generic drugs, which is significant because people over 65 years of age and those who qualify for
state assistance are often on government healthcare programs, which could potentially increase
government costs as a payer of healthcare services (Joseph et al., 2008).
It appears that DTC pharmaceutical promotions affect patients, but they are reluctant to admit
it or are unaware of the influence on them (Joseph et al., 2008). In fact, DTC pharmaceutical
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marketing may have led to social changes in which patients no longer use willpower to change
their health status, but instead, rely on medical interventions (Hoek, 2008). Despite this, the
FDA asserts that they are “unaware of any data supporting the assertion that the public
health…is being harmed, or is likely to be harmed by the Agency’s actions in facilitating
consumer-directed broadcast advertising” (Lyles, 2002). Current regulations, however, have
failed to quell the strong, divergent stakeholder views regarding marketing pharmaceuticals
directly to patients (Lyles, 2002).
In addition to altering patient behaviors, DTC advertising of pharmaceuticals may also alter
current standards and perceptions of liability (Lyles, 2002). Legal precedent holds that
“physicians are the ‘learned intermediary’ between pharmaceutical companies and patients, and
that they are responsible for judging a prescription drug’s benefits and risks for their patients”
(Lyles, 2002). As a result, pharmaceutical companies have been protected from having to warn
patients directly (Lyles, 2002). As seen in Perez v Wyeth Laboratories, Inc., there is growing
concern over this protection from liability. When companies communicate directly with patients,
manufacturer’s liability may increase, particularly if the FDA has issued corrective actions
because of a DCT pharmaceutical advertising campaign (Lyles, 2002).
Without assurance that patients, payers, physicians, and pharmacists all agree that DTC
marketing of pharmaceuticals benefits public health, it is unlikely the practice will continue in its
current form (Friedman & Gould, 2006). While self-imposed industry guidelines are a first step,
legislators are questioning the value of the practice, which ultimately may lead to significant
changes to or cessation of DTC marketing of pharmaceuticals (Friedman & Gould, 2006).
Wakeam (2009) proposes a government regulatory body to provide oversight and control of
product portrayals in the absence of a total ban on DTC pharmaceutical advertising.
Government action may be able to provide appropriate boundaries on pharmaceutical advertising
as a safeguard for patients (Wakeam, 2009).
While not expressly focused on DTC pharmaceutical marketing, the Patient Protection and
Affordable Care Act signed into law on March 23, 2010 has multiple measures that affect
pharmaceutical manufacturers and is likely to influence future DTC pharmaceutical marketing
strategies. Such provisions include elimination of the tax deduction for employers who receive
Medicare Part D retiree drug subsidy payments in 2013; imposing billions of dollars in new
annual fees on the pharmaceutical manufacturing sector on a graduated scale beginning in 2012;
increasing the Medicaid drug rebate percentage for brand name drugs and non-innovator,
multiple source drugs; authorizing the FDA to approve generic drugs and grant manufacturers
twelve years of patent protection; providing incentives to Medicare and Medicaid beneficiaries to
complete behavior modification programs; and requiring pharmaceutical manufacturers to
provide a 50% discount on brand name drugs for prescriptions filled in the Medicare Part D
coverage gap beginning in 2011 (Kaiser Family Foundation, 2010). While it is impossible to
predict the effect on patient-centered pharmaceutical promotions at this point, it is fair to say that
the future of DTC pharmaceutical marketing could look very different; however, changes in
Congressional power resulting from the 2010 mid-term elections may result in changes to
healthcare reform law. Future research is recommended as administrative rules are written and
provisions are enacted. Regardless of the outcomes of healthcare reform, the FDA should act
now to revise DTC pharmaceutical marketing policy.
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Options and Outcomes
In December 2001, the Council of the Royal Pharmaceutical Society of Great Britain stated the
following position on DTC pharmaceutical marketing in that country:
The demand for information about prescribed medicines from patients and the public is likely to
increase, but [direct-to-consumer advertising] DCTA is unlikely to be the best way of providing
it because the aim of advertising is to persuade, not to give balanced information about benefits
and risks. DTCA, moreover, carries a significant risk of exposing more patients to the adverse
effects of new drugs. If DCTA is successful, it may well adversely affect doctor-patient
relationships, distort public health priorities and disrupt the cost controls operated by the
[National Health Service] NHS… (World Health Organization, 2002).
Countries around the world prohibit DTC pharmaceutical marketing for many of the same
reasons. The United States and New Zealand are the only two countries that allow DTC
marketing of pharmaceuticals, albeit both “by omission rather than design” (Hoek and Gendall,
2002). New Zealand successfully self-regulates DTC pharmaceutical marketing, largely because
“…the knowledge that legislation would replace self-regulation if the latter proves ineffective
provides a compelling incentive for the industry to maintain robust and transparent systems of
accountability” (Hoek and Gendall, 2002).
As evidenced by situations such as Perez v Wyeth Laboratories, Inc. and the warning letter
issued to Bayer HealthCare Pharmaceutical, Inc., the United States pharmaceutical
manufacturing industry is unwilling or unable to regulate itself, as in New Zealand. The United
States requires government regulation through the FDA to ensure patients receive fair and
balanced information about prescription medications, including potential drug risks. Although
opponents of DTC pharmaceutical marketing propose rescinding the practice altogether, it is
highly unlikely that this will occur due to the vast resources and immense power and influence of
pharmaceutical manufacturer lobbyists. Short of total reversal, however, the FDA should
immediately revise its guidelines to eliminate the product claims advertisement category, which
promote specific products, by name, for the treatment of specific conditions. Help-seeking and
reminder advertisements should still be allowed, as they provide information on specific
diseases, conditions, and even specific medications, without the negative consequences of
persuading patients to seek brand name prescription medications for self-diagnosed conditions.
Both proponents and opponents of DTC pharmaceutical marketing would agree that patients
would still be informed of conditions they may not know they have and would still be
empowered to talk to their physicians, who have the knowledge of new, existing, and alternative
therapies and can decide the most appropriate course of action with informed, not persuaded,
patients. Pharmaceutical companies may see reduced profit margins if product claims
advertising is not allowed, but as evidenced by Perez v Wyeth Laboratories, Inc., they may also
avoid putting people at risk of adverse effects and potentially large payouts in court settlements
due to increased scrutiny of marketing practices and product liability. Table 2 summarizes the
outcomes of three policy options for key stakeholders; (1) maintain the status quo, (2) totally ban
DTC pharmaceutical marketing, and (3) ban DTC product claims advertisements.
CONCLUSION
The top 25-marketed drugs accounted for $7.2 billion in increased costs in pharmaceutical
spending in the United States from 1998 to 1999, and healthcare costs increased annually by
9.6% between 2000 and 2004, largely due to increased pharmaceutical costs (Joseph et al., 2005;
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Joseph et al., 2007). Pharmaceutical manufacturers enjoy staggering profits, often at the expense
(and sometimes wellbeing) of the American public. Policy-makers question the appropriateness
of continued widespread marketing of pharmaceuticals directly to patients, and courts have
begun looking at who bears the liability of warning patients of the risks of advertised
pharmaceuticals (Perez v Wyeth Laboratories, Inc.) (Lyles, 2002). However, despite growing
costs, disapproval of physicians, and increased scrutiny, the FDA cannot directly link any
negative impacts on public health due to allowing expanded DTC pharmaceutical advertising
(Lyles, 2002). They have yet to uncover a “smoking gun.”
With the signing of the Patient Protection and Affordable Care Act into law on March 23,
2010, lawmakers may have drastically altered the future of DTC pharmaceutical marketing
(Kaiser Family Foundation, 2010). However, changes in Congressional power resulting from the
2010 mid-term elections may result in changes to healthcare reform law. The United States
should not wait on healthcare reform laws to influence DTC pharmaceutical marketing policies,
as it is clear that without regulatory intervention, the industry will continue to flood the airwaves
with product claims advertisements for the next “best” medications and bankroll huge profits,
regardless of the risks or potential negative consequences for consumers. Instead of waiting to
uncover the “smoking gun,” the FDA should proactively protect public health by revising DTC
pharmaceutical marketing policy to eliminate product claims advertisements. Patients would still
receive empowering information, and physicians would be in a better position to determine the
most appropriate course of action, not simply the “as seen on TV” version.
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Table 2a. Summary of DTC pharmaceutical marketing policy options and outcomes in the United States.
Maintain the Status Quo (Do Nothing)
Pharmaceutical
Manufacturers/Industry

•

•

Patients

•

•

•

Vulnerable Populations

•

•
•

•

Physicians

•

•

Pharmaceutical companies will continue to enjoy lucrative returns on advertising
investments. Research shows that for every $1 spent on DTC advertising,
pharmaceutical industry sales increase by $4.20.
Pharmaceutical advertising will continue to be a leader among all advertising
expenditure categories and pharmaceutical costs will continue to rise, contributing to
increases in overall healthcare costs in the United States. Growing scrutiny by
lawmakers and the FDA alike, along with court decisions such as Perez v. Wyeth
Laboratories, Inc., will increase the liability of pharmaceutical manufacturers who
market directly to consumers, putting them at risk of potentially enormous legal fees
and/or settlements.
Although research shows that as a form of information about pharmaceuticals, patients
trust advertising the least; studies also show that patients look favorably on DTC
pharmaceutical advertising as a way to learn about medical conditions and treatments,
and are prompted to talk to their doctors.
Patients will continue to diagnose themselves with conditions they see on television
and will continue to request specific medications from their doctors – 40% do so now,
and of that 40%, over half receive the requested medication.
Patient prescription and healthcare expenses will continue to rise, particularly because
roughly one-third of patients report they prefer brand name over generic medications.

Not all populations are equally impacted by DTC pharmaceutical marketing. Race or
ethnicity, socioeconomic status, gender, and age are significant to the level of
awareness of such marketing and subsequent actions. In general, minorities
(particularly Hispanics) are less aware of DTC pharmaceutical advertisements. Women
are more likely than men to be aware of pharmaceutical advertisements and
subsequently see their doctors about advertised drugs. Low-income individuals
($20,000 per year or less) are less aware of DTC pharmaceutical advertisements, but
report being persuaded by such advertisements to prefer brand name drugs and to
consult a physician when they have symptoms mentioned in advertisements.
Patients with lower literacy levels have low, unbalanced comprehension and recall of
DTC pharmaceutical advertisements.
Senior citizens are more skeptical of DTC pharmaceutical advertising, but are the most
vulnerable consumers. Senior citizens have the highest prescription usage rates, the
lowest DTC pharmaceutical advertisement comprehension and recall rates of all age
groups, yet, when an advertised medication “hits home” they are disproportionately
influenced to act.
DTC pharmaceutical advertisements will continue to miss some target audiences and
disproportionately influence others. Low-income earners and senior citizens will
continue to be persuaded to prefer brand name drugs, which is significant because the
costs of brand name pharmaceuticals are often much higher than generic equivalents.
Research shows that the majority of physicians feel that DTC pharmaceutical
marketing leads to patients asking for and receiving unnecessary prescriptions,
including a preference for brand name drugs where a generic is sufficient. Despite these
findings, physicians continue to prescribe medication when they believe a patient is
expecting it. When faced with a choice of two comparable medications, physicians will
continue to defer to patient preference, even if it alters the physician’s prescribing
methods or may not be the best choice of treatment. In roughly 5% of instances,
doctors prescribe medications simply to appease patients.
Physicians will continue to dislike DTC pharmaceutical marketing, but will also
continue to alter prescribing practices based on patient pressure.
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Table 2b. Summary of DTC pharmaceutical marketing policy options and outcomes in the United States.
Ban DTC Product Claims Advertisements

Pharmaceutical
Manufacturers/Industry

•

•

•

Patients

•

•

Vulnerable Populations

•

Physicians

•

•

•
•
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Pharmaceutical companies will increase physician-directed marketing of specific
drugs for specific conditions, and will simultaneously increase help-seeking and
reminder advertisements directly to consumers.
Pharmaceutical manufacturers may increase costs of brand name prescription
drugs in an effort to offset profit losses likely to result from discontinuing
product claims advertisements.
R&D may initially slow until pharmaceutical manufacturers realize actual
financial impacts and make decisions based on new profit margins. By
marketing drugs without claims of clinical role or effectiveness, fewer consumers
may be impacted by negative consequences and manufacturer liability and
associated costs would greatly diminish.
Both proponents and opponents of DTC pharmaceutical marketing can agree that
help-seeking advertisements will continue to inform patients of potentially
serious medical conditions and symptoms, which will continue to prompt them to
talk to their physicians.
Reminder advertisements may prompt patients to ask their doctors about specific
medications, but they will put less pressure to prescribe that medication on their
doctor if they have not previously convinced themselves that they have the
medical condition that specific drug treats. Patients will be informed, not
persuaded, and fewer will be impacted by potential negative effects from
unnecessary or contraindicated “as seen on TV” pharmaceuticals.
Information received through help-seeking advertisements will still empower
vulnerable populations to talk to their doctors about signs and symptoms of
medical conditions, without disproportionately persuading them to prefer
specific, often expensive medications. Through increased patient-physician
dialogue about various treatment options, acceptance of generic medications may
increase and vulnerable populations may see the same positive health outcomes
along with substantial monetary savings.
Physicians have the best knowledge of new, existing, and alternative therapies
and can decide the best course of action when patients are informed, not
persuaded, and prescribing decisions are put back in the hands of the experts.
Physicians would support scaling back patient-directed pharmaceutical
marketing. Although physician-directed pharmaceutical marketing may increase,
pressure from patients will decrease.
Physicians must continue to seek information from sources beyond just
pharmaceutical representatives, however.
Physician-patient relationships and outcomes are likely to improve as physicians
are able to spend more time talking to patients about options versus deflecting
requests for advertised medications.
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Table 2c. Summary of DTC pharmaceutical marketing policy options and outcomes in the United States.
Pharmaceutical
• Pharmaceutical manufacturers will raise drug prices in an effort to offset DTC
Manufacturers/Industry
marketing profit losses.
• Physician-directed marketing will increase dramatically.
• Research and development (R&D) for new, innovative pharmaceuticals will be
scaled back because the potential return on the substantial R&D investment (of
approximately seven years and $800 million) is minimized.
• Fewer consumers may be impacted by negative consequences and ultimately,
pharmaceutical manufacturers would be less liable and would avoid litigation and
legal fees.
• The vast resources and strength of pharmaceutical industry lobbyists makes a
total ban of DTC pharmaceutical marketing highly unlikely.
• Nearly two-thirds of patients report that they believe doctors prescribe the most
Patients
effective medication, but nearly half also believe that incentives from the
pharmaceutical industry play a role in prescribing patterns. Patients also report
trusting their doctors less now than in the past and believe their health plans are
more concerned with costs than their health.
• Patient distrust is likely to rise and patients may be discouraged from talking to
their doctors about potential medical conditions.
• Some patients may not be aware that symptoms they are experiencing may be due
to a serious medical condition and they could end up with worse, more expensive
outcomes if they seek help later in the disease process.
Vulnerable Populations
• Preference for expensive, brand name medications over generic equivalents will
decrease among senior citizens and low income earners.
• Patient information and awareness will decrease. Physicians will be responsible
for encouraging open dialogue with vulnerable patients to ensure all symptoms
are openly discussed to avoid potential misdiagnoses or missed diagnoses.
• Treatment options and expected outcomes must be easy to understand.
• Vulnerable populations will be less influenced and persuaded by the outside
environment when seeking medical care.
Physicians
• Nearly two-thirds of United States physicians report being in favor of a total ban
on DTC marketing of pharmaceuticals, or at minimum, scaling back the practice.
• Physicians would be relieved of some patient pressures, but would face increased
pressure from the pharmaceutical industry.
• Research shows that physicians who rely only on information from
pharmaceutical manufacturers tend to prescribe inappropriately.
• Physician-patient relationships may suffer if patients lack appropriate information
and question the physician’s motives – research shows that patients already
assume prescribing practices are tied to incentives from pharmaceutical
companies, which erodes trust.
• Patients may not share as much information with physicians and early illness
signs and symptoms may go unnoticed, resulting in worse outcomes.
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